Fluorescent Multiplex IHC for Breast Cancer Tissue Profiling
Cell IDx’s state-of-the-art multiplex immunofluorescence technology allows rapid phenotyping of tumor samples based on multiple markers. Obtain flow cytometry-like data while
retaining the spatial cellular context of different cell populations — all in two hours on a single section. Our individual panels consist of four markers plus DAPI as a nuclear marker to enumerate total cell number.
HER2, ER, PR, Ki-67
Phenotype breast cancer biopsies into the main Luminal A, Luminal B, HER2-enriched, and Triple-negative subtypes with a simple, rapid, two-step procedure using
markers for HER2, ER, PR, and Ki-67. Easily determine phenotype and whether the tumor is of a single type or a mixture of different subtypes with mxIF
CK5, CK14, EGFR, Vimentin
Triple-negative breast cancers exhibit a worse prognosis compared to other sub types. Within this group, those tumors with a basal like phenotype are more aggressive. BC-2 subtyping can be used
individually or simultaneously with or after BC-1 typing to determine whether the triple-negative biopsy exhibits this more aggressive basal-like
phenotype by expression of CK5, CK14, EGFR, and Vimentin markers.
Please select the appropriate panel for use with your imaging scanner or microscope.
Order from our range of available panels below or contact us to create a custom RUO panel for you. Stain sequential sections with our tumor and immune panels to analyze
tumor infiltrating immune cells.
Click on Catalog # to view detailed product information.
Add to Cart
BC-1A Multiplex Panel - Human HER2, ER, PR, Ki-67
Kit for fluorescent multiplex IHC staining of human HER2, ER, PR, Ki-67, detection with 490, 550, 650, 750 nm fluors